key: cord-0762282-0grtynmh
authors: Franchini, Massimo; Glingani, Claudia; Morandi, Mario; Corghi, Giovanni; Cerzosimo, Sara; Beduzzi, Gloria; Storti, Andrea; Di Stasi, Vincenza; Rastrelli, Giulia; Vignozzi, Linda; Mengoli, Carlo; Garuti, Martina; Beccaria, Massimiliano; Inglese, Francesco; Caruso, Beatrice; Petilino, Roberto Antonio; Amato, Massimo; Nicchio, Michele; Pagani, Mauro; Bellani, Angela; Castelli, Gianpaolo; Casari, Salvatore; De Donno, Giuseppe
title: Safety and efficacy of convalescent plasma in elderly COVID-19 patients: the RESCUE trial
date: 2021-02-08
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2021.01.010
sha: 5d8c1692e08b6db3aa250d8e9a63d69e28b046d7
doc_id: 762282
cord_uid: 0grtynmh

Objective To assess the safety and efficacy of convalescent plasma (CP) transfusion in elderly people with moderate to severe COVID-19 living in a long-term care facility (LTCF). Patients and Methods Twenty-two consecutive elderly COVID-19 patients living in a LTCF in Lombardy (Italy) who were given CP during the period May 15-July 31, 2020 were enrolled in a prospective cohort study. Their clinical, instrumental and laboratory parameters were assessed following the CP treatment. Overall mortality rate in this group was compared with that recorded in other LCTF in Lombardy during the 3-month period from March-May 2020. Results Of the 22 patients enrolled, 68.2% (n=15) received one CP unit, 27.3% (n=6) received two units and 4.5% (n=1) received three units. Of the CP units transfused, 76.7% (23/30) had a neutralizing antibody titer ≥1:160. No adverse reactions were recorded during or after CP administration. Improvements of clinical, functional, radiological and laboratory parameters during the 14 days following CP transfusion were observed in all 19 patients who survived. Viral clearance was achieved in all patients by the end of follow-up (median 66 days, IQR 48-80 days). The overall mortality rate was 13.6% (3/22), which compared favorably with that in the control group (38.3%, 281/733, P=0.02) and corresponded to a 65% reduction of mortality risk. Conclusion Early administration of CP with an adequate anti-SARS-CoV-2 antibody-titer to elderly, symptomatic, COVID-19 patients in a LTCF was safe and effective in eliminating the virus, restoring patients’ immunity and blocking the progression of COVID-19, thereby improving patients’ survival.

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, originating from the city of Wuhan in the Republic of China at the end of 2019, had already affected approximately 28 million people and caused nearly 900,000 deaths worldwide as of September 16, 2020 , and the rates are still increasing, according to World Health Organization (WHO) bulletins. 1 As the outbreak became an epidemic and rolled out through the world to become a full-blown pandemic, Italy was the first western country to feel the full brunt of the coronavirus disease 2019 (COVID- 19) . 2 The Italian region of Lombardy, which has a population (about 11 million people) similar to that of Wuhan, was devastated by a wave of infections, or rather a "tsunami", at the end of February, 2020. 3 Thousands of patients with severe COVID-19 respiratory symptoms requiring hospital admission arrived contemporaneously at the emergency rooms of many Lombard hospitals, quickly overwhelming the capacity of these facilities to admit patients. 4 More than one-third of all cases of COVID (101,119/272,912) and nearly half of the total COVID-19-related deaths recorded in Italy (16,876/35,507 , data updated on September 16, 2020) occurred in Lombardy, generating an unprecedented health and social emergency in the region. 5 Among COVID-19 patients, elderly people are more severely affected. 6 The mean age of patients dying of SARS-CoV-2 infection in Italy was 80 years (interquartile range, 74-88 years), 5 and a similar pattern was observed in other countries, 6-8 especially among hospitalized patients. 9 ,10 A particularly critical situation was observed among elderly COVID-19 patients living in long-term care facilities (LTCF) in Italian regions hit more heavily by SARS-CoV-2 infection. Indeed, during the 3-month period from March-May 2020, more than 50% of deaths recorded among the 678 accredited LTCF in Lombardy were caused by COVID-19. 11 Elderly subjects living in LTCF are at increased risk of morbidity and mortality associated with COVID-19 because of their chronic illnesses and the impact of congregate housing on viral spread. [12] [13] [14] Unfortunately, given the emergency situation, most of these elderly patients died in their LTCF without receiving adequate treatment or supportive care in a hospital setting. To try to stop this silent hecatomb and considering J o u r n a l P r e -p r o o f our positive experience on the early use of convalescent plasma (CP) in patients with moderate to severe COVID-19, 15,16 we designed and conducted an interventional trial, the RESCUE study (Realtime Evaluation of Safety and efficacy of Convalescent plasma Units transfused to Elderly patients with , to assess the safety and potential efficacy of hyperimmune plasma infusions in elderly patients with moderate to severe forms of COVID-19 living in LTCF.

Between May 15, 2020 and July 31, 2020, 22 consecutive elderly residents in LTCF with COVID-19 were enrolled in this prospective cohort study, which was registered at clinicaltrials.gov as NCT04569188 and approved by the local Ethical committee on May 15, 2020. Follow-up was closed on September 15, 2020. A LCTF (called "Green Park") was identified for the conduction of this study, fundamentally for the following reasons: proximity to the city hospital of Mantua, a large number of residents (n=240, mostly not self-sufficient with aging-related chronic diseases) and the presence of well-trained, experienced medical and nursing staff with the availability of laboratory and imaging equipment. In addition, to avoid cross-infections, during the COVID-19 outbreak the facility was divided into two separate areas, one for COVID-19 patients with specific personnel, and another for COVID-19-free residents. A medical team from the Respiratory Unit of Mantua City Hospital was responsible for the initial clinical evaluation of SARS-CoV-2 infected patients to identify subjects potentially eligible for inclusion in the study. The inclusion criteria were: (i) elderly patients (≥65 years old) with a nasopharyngeal swab positive for SARS-CoV-2 by polymerase chain reaction (PCR) assay; (ii) new onset or worsening of recent onset respiratory symptoms (<10 days); (iii) evidence of pulmonary infiltrates by chest imaging and respiratory distress defined as moderate (>24 breaths/minute, oxygen saturation <95% in room air, partial pressure of arterial oxygen to fraction of inspired oxygen ratio [P AO2 /F IO2 ] <300) or severe (>30 J o u r n a l P r e -p r o o f breaths/minute, oxygen saturation <93% in room air, P AO2 /F IO2 <200); (iv) the patient's signed informed consent; and (v) no participation in other clinical trials. Exclusion criteria were: (i) a diagnosis of moderate to severe COVID-19 present for >10 days; (ii) proven hypersensitivity or allergic reaction to plasma, blood products or immunoglobulins; (iii) manifest desire not to be included in the research protocol. Patients meeting the inclusion criteria were enrolled in the protocol of CP infusion and the following biochemical examinations were performed: blood group typing, blood count, nasopharyngeal swabs for SARS-CoV-2 RNA detected by reverse transcriptase PCR assay, measurements of C-reactive protein (CRP), lactate dehydrogenase (LDH), interleukin-6 (IL-6), ferritin, creatinine, D-dimer, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels and a chemiluminescent immunoassay for anti-SARS-CoV-2 IgG antibodies (LIAISON SARS-CoV-2 IgG, DiaSorin, Vercelli, Italy). The laboratory tests were carried out in the Central Laboratory of the city hospital of Mantua. In addition, clinical and instrumental monitoring (chest ultrasound or chest radiography) was performed. Patients' concomitant therapies at enrolment and during follow-up were also recorded. All instrumental and laboratory tests, with the exception of blood group typing, which was performed at baseline and then checked before each CP transfusion, were performed on days +1 (baseline, before CP transfusion), +3, +5, +7 and +14 after CP infusion and the results, along with clinical evaluation, were entered into a Case Report Form. At the end of the follow-up, each patient enrolled in the study underwent final clinical, instrumental (chest ultrasound) and laboratory (SARS-CoV-2 PCR testing on nasopharyngeal swab) evaluations. All these procedures were carried out directly by the medical and nursing staff of the LTCF, according to the protocol and with the active supervision of chest physicians of the Respiratory Unit of Mantua city hospital.

The primary outcome of this study was to evaluate the efficacy of early administration of CP in elderly patients with moderate to severe COVID-19, measured as the rate of improvement of J o u r n a l P r e -p r o o f clinical symptoms and laboratory and imaging tests following CP transfusion and the prevention of progression of patients' symptoms and need for hospitalization. A secondary outcome was the safety of CP treatment, measured as the rate of adverse reactions to CP transfusion. The type, degree and outcome of adverse events occurring during or after (within 72 hours) CP transfusion were recorded, according to the Guideline on Good Pharmacovigilance Practices of the European Medicines Agency https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-goodpharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf). Another secondary clinical outcome was the overall mortality rate at 28 days and at the end of follow-up in the CP treatment group compared with that of a cohort of SARS-CoV-2-infected subjects not receiving CP (control group), but comparable in terms of demographic characteristics (elderly subjects living in LTCF in Lombardy) and follow-up period (March-May 2020). These data were retrieved from the Italian national survey on the contagion by SARS-CoV-2 in LTCF conducted by the Italian National Institute of Health (ISS). 11 Finally, another secondary outcome measure was the proportion of patients with conversion of nasopharyngeal swab viral PCR testing from positive to negative, assessed on days +3, +7, +14 and at the end of the follow-up.

Eligible donors were either males or nulliparous females aged between 18-65 years, weighing over 50 kg, with a laboratory confirmed diagnosis of SARS-CoV-2 infection, which had completely resolved at least 14 days prior to donation with two negative SARS-CoV-2 PCR tests from nasopharyngeal swabs collected 24 hours apart. All routine screening tests for blood donors, including ABO blood grouping, Rh phenotype, complete blood count, and screening for human immunodeficiency virus, hepatitis B, C, A and E viruses, parvovirus and syphilis, were conducted according to Italian regulations and the indications of the Italian National Blood Center. 17 Hyperimmune plasma was collected through a plasmapheresis procedure using a cell separator and processed and stored in agreement with national CP regulations. 17, 18 A plasma volume of about 600 J o u r n a l P r e -p r o o f mL was collected during each procedure and immediately divided into two bags, each corresponding to a therapeutic CP unit of 300 mL. Collected CP had an anti-SARS-CoV-2 neutralizing titer of 1:80 or higher. The neutralization test for the identification of anti-SARS-CoV-2-neutralizing antibodies was performed at the Molecular Virology Unit of the University Hospital of Pavia and was based on the determination of cytopathic effect, as previously described. 15 The CP transfusions were performed by medical and nursing staff. CP recipients were transfused with one to three units of ABO type-compatible CP, according to the clinical response. All the procedures were performed in agreement with the routine procedures of the Transfusion Service of Mantua.

Continuous variables are reported as mean (± standard deviation) or median and interquartile range (IQR) as appropriate according to distribution, while categorical data are reported as numbers and percentages. Comparisons between groups were carried out with an independent t test or Mann-Whitney U test for continuous variables and chi-squared test or Fisher's exact test for categorical variables, as appropriate. All statistical tests were two-sided, and associations were considered statistically significant when the values were below a nominal level of 0.05 (P<0.05). A cohort study with equal follow-up time per subject was designed. A 2x2 frequency table was set up, reporting the incidence of death in treated patients and in untreated (control) patients. The surviving patients in both groups were enumerated. The inference concerning the null hypothesis of no-effect by treatment was obtained by Pearson's chi-squared test and Fisher's exact test. Risk was the proportion of subjects who became cases (due to an event, i.e., death). Point estimates (means) and confidence intervals were calculated for risk ratio, risk difference, along with the number needed to treat to prevent an event. Calculations were done with Stata 16.1 software.

The baseline demographic and clinical characteristics of the 22 elderly COVID-19 patients enrolled in the RESCUE study are reported in Table 1. The median age was 87 years (IQR, 82-90 years) with an equal distribution between sexes (male/female ratio: 1.0). The subjects' median body mass index (BMI) at enrollment was normal (21. (60.0%) had a titer of 1:160 and five (16.7%) had a titer of 1:320. The median interval between symptom onset and the first CP transfusion was 7 days (IQR, 4.5-8 days). In cases that a second unit was administered, the median interval between transfusion of the first and second CP units was 3 days (IQR 3-12 days). The only patient who received a third CP unit was given the third unit 3 days after the second one. No adverse reactions were recorded during or after the CP transfusions.

The course of clinical, functional, radiological and laboratory parameters during the 14 days following CP transfusion is presented in Table 2 for the 19 survivors. Oxygen saturation and P AO2 /F IO2 ratio improved significantly following the CP transfusion and this effect was evident already by post-infusion day +3 for oxygen saturation and by day +7 for P AO2 /F IO2 ratio. In parallel, Notably, the concentration of anti-SARS-CoV-2 IgG antibodies increased following CP infusion (from a median baseline level of 127.0 U/mL to a median level of 157.0 U/mL at day +3 after CP infusion) reaching a plateau at day +7 (158.0 U/mL) and then increasing again by day +14 (194 U/mL).

The overall mortality rate was 13.6% (3/22) ( Table 3) . Of the three patients who did not survive, one, a 94-year old male with moderate COVID-19, died 3 days after CP infusion due to massive hemorrhage related to a sudden rupture of the abdominal aorta (this death was judged unrelated to . The other two elderly males, aged 79 and 83 years, both with severe COVID-19 J o u r n a l P r e -p r o o f (bilateral lung infiltrates, >3 comorbidities and P AO2 /F IO2 ratio of 130 and 140, respectively) were admitted to hospital because of worsening of respiratory failure and died of progression of the disease 7 and 9 days after the CP transfusion, respectively. The search for SARS-CoV-2 viral nucleic acid performed on day +7 resulted negative. A statistically significant difference was found between the overall mortality in our study and that observed in a similar population of elderly COVID-19 patients living in LTCF in Lombardy 11 (13.6% versus 38.3; P=0.02) ( Table 3 ). The number needed to treat (NNT) to prevent an event (in this analysis, death) was 4.05 (95% confidence interval: 2.53, 10.07).

Regarding viral clearance following the CP infusions, 85.7% of patients became negative for SARS-CoV-2 RNA assayed by reverse transcriptase PCR within 3 days of the CP infusion, a proportion that increased progressively up to 95.2% by 14 days. At the end of the follow-up period (median 66 days), all the 19 elderly patients who were alive were negative for SARS-CoV-2 viral nucleic acid. They were transferred to the COVID-19-free unit of the LTCF. As no new COVID-19 cases were recorded among LTCF residents, the COVID-19-dedicated area was definitively closed on September 1 st , 2020.

Several studies have reported that old age is a significant risk factor for COVID-19 mortality, with frailty and virus-related decompensation of comorbidities being among the most important causes contributing to the poorer outcome in elderly patients with this disease. 7-10 On this background, it is not surprising that a particularly critical situation has been observed among elderly residents of LTCF in which the virus was able to circulate relatively undisturbed infecting many other hosts and causing high COVID-19 morbidity and mortality rates. 19 For instance, in the Italian national survey by the ISS, in the period from March to May 2020, the COVID-19 mortality rate in LTCF in J o u r n a l P r e -p r o o f Lombardy was more than double the national rate (6.5% versus 3.1%, respectively). 11 Furthermore, the lack of special surveillance systems and testing strategies may have led to a significant underascertainment and under-reporting of cases, contributing to a general underestimation of the disease burden and mortality in LTCF. As a consequence, during the COVID-19 pandemic, in some metropolitan areas of Lombardy we seriously risked losing an entire generation, that of elderly people. With the aim of rescuing these people, we conducted this cohort study, the first exploring the safety and efficacy of CP in a population composed exclusively of extremely old (median age, 87 years) COVID-19 patients. The results of our study conducted on a cohort of 22 patients were somewhat surprising: CP reduced the mortality risk by 65% compared to that in a control population, enabling the saving of one life for every four patients treated. Although the overall crude mortality rate was 13.6%, the COVID-19-related mortality rate was 9.1%, very similar to the mortality rate observed in the US Food and Drug Administration (FDA) expanded access program (EAP). 22 The ability of CP to block the progression of COVID-19 observed in our study was also found in a recently published, randomized, placebo-controlled trial, 23 which showed that early (within 72 hours) administration of high-titer CP to mildly ill, older adults with COVID-19 reduced the progression of the disease. The median time of CP administration after symptom onset was significantly longer in our study (7 days). It was not, however, possible to stratify our cohort according to the time of CP infusion because of the small number of patients enrolled and of events (i.e., deaths) recorded. The clinically beneficial effects of CP were also clearly evident from the functional respiratory and laboratory indices immediately after its infusion, already at 72 hours. In particular, the rapid and consistent decreases of all the main laboratory parameters, including CRP, IL-6 and ferritin levels, document the anti-inflammatory properties of CP, in agreement with data available from previously published studies. [16] [17] [18] [19] [20] The improvement of D-dimer levels is also of relevance, considering the frequency of thromboembolic complications during COVID-19; 21 this phenomenon is probably secondary to the anti-inflammatory activity of the CP and documents the close links between inflammation and hypercoagulability. However, the most intriguing laboratory J o u r n a l P r e -p r o o f finding of our study is probably the increase of anti-SARS-CoV-2 IgG antibodies over time which, after a first peak phase linked to the passively CP-infused antibodies, reached a steady state and then increased again later by day +14 after infusion. This second wave was probably due to the active production of antibodies by the patient's own lymphocytes, documented by the progressive increase of lymphocyte count following CP infusion. This finding may shed new light on the potential mechanisms of action of CP.

In addition to the efficacy data, our study showed the absolute safety of CP transfusion, already evidenced by robust data from the US FDA EAP. 22 The most probable explanation of these positive results lies, in our opinion, in the timing and dosing of CP: the early administration (median 7 days after symptom onset) of an adequate dose (76.7% of units had a neutralizing titer of at least 1:160) of CP was able to eradicate the virus in all patients, halting the progression of COVID-19 and thus avoiding the need for hospital admission (a particularly poor prognostic factor) in all but two patients. In addition, the clearance of the virus in these patients blocked circulation of the pathogen within the LTCF preventing the infection of other elderly residents.

The main limitation of our study is the small number of patients enrolled and the non-randomized design. Nevertheless, the population of patients enrolled in this single-center study was highly homogeneous and well-studied with rigorous application of selection criteria and close and careful clinical and laboratory follow-up. Another potential limitation of our study could be the control group selected for the survival analysis. We chose to extract data from the ISS report 11 in order to have a control population that corresponding as closely as possible to the CP treatment group in terms of demographic characteristics, health status (elderly subjects living in similar LCTF in the same geographical area) and period of observation. In addition, the high number (nearly 90%) of not self-sufficient residents in our LTCF certainly did not confer any survival advantage to the treatment group over controls. Notably, the mortality rate observed in the present study conducted in elderly patients with moderate to severe COVID-19 was comparable to that observed in other trials conducted on younger subjects. 22, 24, 25 These results, therefore, further confirm recently J o u r n a l P r e -p r o o f published evidence that biological age and frailty, which are inter-dependently connected, rather than chronological age, are important predictors of disease severity and survival in COVID-19 patients. 26, 27 

The results of our study document for the first time the feasibility, safety and efficacy of a CP transfusion program for COVID-19 patients in a LTCF setting. The rapid COVID-19 diagnosis and early administration of adequately anti-SARS-CoV-2 antibody-titrated CP was, in our opinion, the winning card as it neutralized the virus and restored patients' immunity, blocking the progression of the viral respiratory disease. As a consequence of this beneficial effect, hospitalization was avoided in a consistent number of patients, who were not therefore exposed to risk factors for shortened survival (e.g., prolonged immobilization, nosocomial co-infections and co-morbidities).

Nevertheless, our study further confirms that chronological aging and frailty do not necessarily coexist and that even very old people with severe COVID-19 deserve to be treated for this dreaded infectious disease as they have the same chance of responding to CP as younger COVID-19 patients. Indeed, CP treatment could be preferred to anti-viral synthetic drugs in elderly COVID-19 patients because of its independence from renal function and its lack of adverse effects and interactions with other concomitantly administered drugs. In conclusion, we are proud to share the results of our study with the international scientific community. Although further trials on larger numbers of elderly patients are needed to confirm our extremely positive preliminary results, we hope our findings will help clinicians in Italy and other countries, in which the pandemic is still taking a dramatic toll, to rescue our grandparents, our collective memory, from severe COVID-19. Abbreviations: CP: convalescent plasma; IQR: interquartile range; NS: not significant; P AO2 /F IO2 : partial pressure of arterial oxygen to fraction of inspired oxygen ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IL-6, interleukin-6; LDH, lactate dehydrogenase.

J o u r n a l P r e -p r o o f Table 3 . Comparison of overall mortality rate at the end of follow-up between the group of patients given convalescent plasma and the control group. 

WHO. Coronavirus disease (COVID-2019). Situation reports

The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy

Hypothesis to explain the severe form of COVID-19 in Northern Italy

COVID-19 -Situation in Italy

Age-related morbidity and mortality among patients with COVID-19

Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China

From causes of aging to death from COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

A survey on COVID-19 infection in long-stay residential care homes

Improving preparedness for and response to coronavirus disease 19 (COVID-19) in long-term care hospitals in Korea

Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks

Ageing and COVID-19: What is the role for elderly people?

Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol

Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial

Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy

Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19

European Centre for Disease Prevention and Control. Surveillance of COVID-19 in longterm care facilities in the EU/EEA

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

Fundación INFANT-COVID-19 Group. Early high-titer plasma therapy to prevent severe Covid-19 in older adults

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv

Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Association of frailty with mortality in older inpatients with Covid-19: a cohort study

The authors thank Dr. Rachel Stenner for her revision of the language of this manuscript.J o u r n a l P r e -p r o o f